{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T14:47:12Z","timestamp":1773758832806,"version":"3.50.1"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Transthyretin cardiac amyloidosis (ATTR CA) is a progressive disease arising from the deposition of amyloid fibrils in the myocardium. Cardiac magnetic resonance (CMR) tissue characterization imaging, including myocardial extracellular volume (ECV) fraction, is used to detect amyloid infiltration, but the identification of early-stage disease is challenging. We sought to describe the phenotype of low burden ATTR CA on CMR and identify imaging features that allow differentiation from potential disease mimickers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Eighty-three patients with ATTR CA and prior contrast-enhanced CMR were stratified by quartiles of ECV into low (ECV \u226443%) or higher (ECV &amp;gt;43%) burden groups. Global and regional function and myocardial tissue characterization were used to phenotype disease. Receiver operating characteristic analysis was performed to assess the diagnostic performance of CMR for distinguishing low burden ATTR CA from hypertensive heart disease (HHD) and mild hypertrophic cardiomyopathy (HCM). Among 22 patients with low ECV burden, CMR measures of amyloid infiltration predominantly affected the basal left ventricular (LV) segments with progressive involvement of the mid and apical regions at higher ECV. Global myocardial late gadolinium enhancement (LGE) and ECV showed high accuracy for differentiating low burden ATTR CA from HHD and mild HCM, area under the curve (AUC) of 0.99 and 0.97, respectively, compared to strain-based measures, AUC 0.47\u20130.82.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Tissue characterization imaging (myocardial ECV and LV LGE) can be used to distinguish low burden ATTR from potential disease mimickers and appears to outperform traditional strain-based measures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjimp\/qyag038","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T12:41:28Z","timestamp":1772196088000},"source":"Crossref","is-referenced-by-count":0,"title":["Low burden transthyretin cardiac amyloidosis on cardiac magnetic resonance: comprehensive phenotyping and distinction from hypertrophic phenocopies"],"prefix":"10.1093","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9807-2816","authenticated-orcid":false,"given":"Bethlehem","family":"Mengesha","sequence":"first","affiliation":[{"name":"University of Ottawa Heart Institute, University of Ottawa , 40 Ruskin street, Ottawa, Ontario , K1Y 4W7","place":["Canada"]},{"name":"The Ottawa Hospital, University of Ottawa , 501 Smyth Rd, Ottawa, Ontario K1H 8L6"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suman","family":"Prabhakar","sequence":"additional","affiliation":[{"name":"University of Ottawa Heart Institute, University of Ottawa , 40 Ruskin street, Ottawa, Ontario , K1Y 4W7","place":["Canada"]},{"name":"The Ottawa Hospital, University of Ottawa , 501 Smyth Rd, Ottawa, Ontario K1H 8L6"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary R","family":"Small","sequence":"additional","affiliation":[{"name":"University of Ottawa Heart Institute, University of Ottawa , 40 Ruskin street, Ottawa, Ontario , K1Y 4W7","place":["Canada"]},{"name":"The Ottawa Hospital, University of Ottawa , 501 Smyth Rd, Ottawa, Ontario K1H 8L6"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Chih","sequence":"additional","affiliation":[{"name":"University of Ottawa Heart Institute, University of Ottawa , 40 Ruskin street, Ottawa, Ontario , K1Y 4W7","place":["Canada"]},{"name":"The Ottawa Hospital, University of Ottawa , 501 Smyth Rd, Ottawa, Ontario K1H 8L6"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Thornhill","sequence":"additional","affiliation":[{"name":"University of Ottawa Heart Institute, University of Ottawa , 40 Ruskin street, Ottawa, Ontario , K1Y 4W7","place":["Canada"]},{"name":"The Ottawa Hospital, University of Ottawa , 501 Smyth Rd, Ottawa, Ontario K1H 8L6"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4529-3102","authenticated-orcid":false,"given":"D Ian","family":"Paterson","sequence":"additional","affiliation":[{"name":"University of Ottawa Heart Institute, University of Ottawa , 40 Ruskin street, Ottawa, Ontario , K1Y 4W7","place":["Canada"]},{"name":"The Ottawa Hospital, University of Ottawa , 501 Smyth Rd, Ottawa, Ontario K1H 8L6"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"2026031708270064000_qyag038-B1","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.jchf.2024.07.003","article-title":"The pathophysiological and therapeutic implications of cardiac light-chain amyloidosis compared with transthyretin amyloidosis","volume":"12","author":"Schilling","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026031708270064000_qyag038-B2","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis","volume":"135","author":"Maurer","year":"2017","journal-title":"Circulation"},{"key":"2026031708270064000_qyag038-B3","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1148\/radiol.2015141744","article-title":"Differential myocyte responses in patients with cardiac transthyretin amyloidosis and light-chain amyloidosis: a cardiac MR imaging study","volume":"277","author":"Fontana","year":"2015","journal-title":"Radiology"},{"key":"2026031708270064000_qyag038-B4","doi-asserted-by":"crossref","first-page":"1154594","DOI":"10.3389\/fcvm.2023.1154594","article-title":"Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials","volume":"10","author":"Tomasoni","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"2026031708270064000_qyag038-B5","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026031708270064000_qyag038-B6","first-page":"e000029","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging","volume":"14","author":"Dorbala","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026031708270064000_qyag038-B7","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"2026031708270064000_qyag038-B8","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jcmg.2018.02.006","article-title":"Native T1 and extracellular volume in transthyretin amyloidosis","volume":"12","author":"Martinez-Naharro","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026031708270064000_qyag038-B9","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"2026031708270064000_qyag038-B10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"key":"2026031708270064000_qyag038-B11","doi-asserted-by":"crossref","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"key":"2026031708270064000_qyag038-B12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12968-020-00607-1","article-title":"Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update","volume":"22","author":"Kramer","year":"2020","journal-title":"J Cardiovasc Magn Reson"},{"key":"2026031708270064000_qyag038-B13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12968-020-00610-6","article-title":"Standardized image interpretation and post-processing in cardiovascular magnetic resonance\u20142020 update: Society for Cardiovascular Magnetic Resonance (SCMR): Board of Trustees Task Force on Standardized Post-Processing","volume":"22","author":"Schulz-Menger","year":"2020","journal-title":"J Cardiovasc Magn Reson"},{"key":"2026031708270064000_qyag038-B14","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.amjcard.2007.05.061","article-title":"Right ventricular involvement in hypertrophic cardiomyopathy","volume":"100","author":"Maron","year":"2007","journal-title":"Am J Cardiol"},{"key":"2026031708270064000_qyag038-B15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12968-020-00683-3","article-title":"Reference ranges (\u201cnormal values\u201d) for cardiovascular magnetic resonance (CMR) in adults and children: 2020 update","volume":"22","author":"Kawel-Boehm","year":"2020","journal-title":"J Cardiovasc Magn Reson"},{"key":"2026031708270064000_qyag038-B16","doi-asserted-by":"crossref","first-page":"e014645","DOI":"10.1161\/CIRCIMAGING.122.014645","article-title":"Optimal echocardiographic parameters to improve the diagnostic yield of tc-99m-bone avid tracer cardiac scintigraphy for transthyretin cardiac amyloidosis","volume":"15","author":"Cuddy","year":"2022","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026031708270064000_qyag038-B17","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1161\/hc0402.102975","article-title":"Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association","volume":"105","author":"Cerqueira","year":"2002","journal-title":"Circulation"},{"key":"2026031708270064000_qyag038-B18","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1067\/j.cpradiol.2016.11.008","article-title":"Evaluation of myocardial strain in patients with amyloidosis using cardiac magnetic resonance feature tracking","volume":"46","author":"Pandey","year":"2017","journal-title":"Curr Probl Diagn Radiol"},{"key":"2026031708270064000_qyag038-B19","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/eurheartj\/ehi258","article-title":"Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies","volume":"26","author":"Mahrholdt","year":"2005","journal-title":"Eur Heart J"},{"key":"2026031708270064000_qyag038-B20","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3233\/JND-190415","article-title":"The added value of cardiac magnetic resonance in muscular dystrophies","volume":"6","author":"Lamacie","year":"2019","journal-title":"J Neuromuscul Dis"},{"key":"2026031708270064000_qyag038-B21","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/eurheartj\/ehy713","article-title":"Prevalence and prognosis of ischaemic and non-ischaemic myocardial fibrosis in older adults","volume":"40","author":"Shanbhag","year":"2019","journal-title":"Eur Heart J"},{"key":"2026031708270064000_qyag038-B22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.yjmcc.2012.11.006","article-title":"Syndecan-4 signaling via NFAT regulates extracellular matrix production and cardiac myofibroblast differentiation in response to mechanical stress","volume":"54","author":"Herum","year":"2013","journal-title":"J Mol Cell Cardiol"},{"key":"2026031708270064000_qyag038-B23","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1877-1173(10)93013-5","article-title":"Heparan sulfate proteoglycans in amyloidosis","volume":"93","author":"Zhang","year":"2010","journal-title":"Prog Mol Biol Trans Sci"},{"key":"2026031708270064000_qyag038-B24","doi-asserted-by":"crossref","first-page":"H573","DOI":"10.1152\/ajpheart.00525.2008","article-title":"Left ventricular regional wall curvedness and wall stress in patients with ischemic dilated cardiomyopathy","volume":"296","author":"Zhong","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026031708270064000_qyag038-B25","doi-asserted-by":"crossref","first-page":"H610","DOI":"10.1152\/ajpheart.2001.280.2.H610","article-title":"Regional nonuniformity of normal adult human left ventricle","volume":"280","author":"Bogaert","year":"2001","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026031708270064000_qyag038-B26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/13506120701815373","article-title":"Gender-related risk of myocardial involvement in systemic amyloidosis","volume":"15","author":"Rapezzi","year":"2008","journal-title":"Amyloid"},{"key":"2026031708270064000_qyag038-B27","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10741-023-10339-w","article-title":"Sex differences in transthyretin cardiac amyloidosis","volume":"29","author":"Aimo","year":"2024","journal-title":"Heart Fail Rev"}],"container-title":["European Heart Journal - Imaging Methods and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjimp\/advance-article-pdf\/doi\/10.1093\/ehjimp\/qyag038\/67175281\/qyag038.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjimp\/article-pdf\/4\/1\/qyag038\/67175281\/qyag038.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjimp\/article-pdf\/4\/1\/qyag038\/67175281\/qyag038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T12:27:09Z","timestamp":1773750429000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjimp\/article\/doi\/10.1093\/ehjimp\/qyag038\/8502214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjimp\/qyag038","relation":{},"ISSN":["2755-9637"],"issn-type":[{"value":"2755-9637","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1,1]]},"article-number":"qyag038"}}